|
|
| | TRAF6 Peptide Basic information |
| Product Name: | TRAF6 Peptide | | Synonyms: | TRAF6 Peptide;L-Lysine, L-alanyl-L-alanyl-L-valyl-L-alanyl-L-leucyl-L-leucyl-L-prolyl-L-alanyl-L-valyl-L-leucyl-L-leucyl-L-alanyl-L-leucyl-L-leucyl-L-alanyl-L-prolyl-L-α-glutamyl-L-seryl-L-alanyl-L-serylglycyl-L-prolyl-L-seryl-L-α-glutamyl-L-α-aspartyl-L-prolyl-L-seryl-L-valyl-L-asparaginyl-L-phenylalanyl-L-leucy...;TRAF6(cellpermeable)、TRAF6 Peptide | | CAS: | 852805-92-6 | | MF: | C145H238N34O44 | | MW: | 3161.69 | | EINECS: | | | Product Categories: | | | Mol File: | 852805-92-6.mol |  |
| | TRAF6 Peptide Chemical Properties |
| Boiling point | 2698.5±65.0 °C(Predicted) | | density | 1.278±0.06 g/cm3(Predicted) |
| | TRAF6 Peptide Usage And Synthesis |
| Uses | TRAF6 peptide is a specific TRAF6-p62 inhibitor. TRAF6 peptide potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke[1]. | | References | [1] Wooten, Marie W. Substances interfering with TRAF6-p62 interaction for inhibiting intracellular aggregate formation and methods for screening for such substances. Patent WO2005050170A2. |
| | TRAF6 Peptide Preparation Products And Raw materials |
|